We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
176
Phathom Pharmaceuticals
PHAT
$660M
$1.22M 0.28%
112,139
+54,153
+93% +$618K
BNTX icon
177
BioNTech
BNTX
$24.3B
$1.2M 0.28%
12,844
+3,940
+44% +$371K
HRZN icon
178
Horizon Technology Finance
HRZN
$314M
$1.19M 0.28%
252,455
+108,487
+75% +$469K
EXEL icon
179
Exelixis
EXEL
$14.1B
$1.19M 0.28%
21,887
+1,236
+6% +$60.2K
BMRN icon
180
BioMarin Pharmaceuticals
BMRN
$12.5B
$1.19M 0.28%
20,784
+4,948
+31% +$271K
TBPH icon
181
Theravance Biopharma
TBPH
$885M
$1.19M 0.28%
69,885
+23,421
+50% +$388K
IOVA icon
182
Iovance Biotherapeutics
IOVA
$4.24B
$1.19M 0.28%
285,020
-98,743
-26% -$375K
ADMA icon
183
ADMA Biologics
ADMA
$1.93B
$1.19M 0.28%
141,642
+98,959
+232% +$902K
TARS icon
184
Tarsus Pharmaceuticals
TARS
$3.66B
$1.18M 0.28%
18,771
+8,393
+81% +$536K
UTHR icon
185
United Therapeutics
UTHR
$21.5B
$1.15M 0.27%
2,130
+423
+25% +$238K
AXSM icon
186
Axsome Therapeutics
AXSM
$10.7B
$1.12M 0.26%
4,557
-1,141
-20% -$247K
VSTM icon
187
Verastem
VSTM
$665M
$1.08M 0.25%
283,630
+255,256
+900% +$1.23M
ARDX icon
188
Ardelyx
ARDX
$878M
$1.04M 0.24%
204,373
+68,419
+50% +$418K
OCCI
189
OFS Credit Co
OCCI
$70.2M
$1M 0.23%
392,323
-69,832
-15% -$215K
PSEC icon
190
Prospect Capital
PSEC
$1.14B
$990K 0.23%
428,612
+90,666
+27% +$223K
LEGN icon
191
Legend Biotech
LEGN
$3.44B
$936K 0.22%
32,419
-5,405
-14% -$146K
TCPC icon
192
BlackRock TCP Capital
TCPC
$336M
$870K 0.2%
258,829
+11,514
+5% +$44.7K
XFLT
193
XAI Floating Rate & Alternative Income Trust
XFLT
$291M
$802K 0.19%
45,722
-10,036
-18% -$182K
FSK icon
194
FS KKR Capital
FSK
$3.32B
$785K 0.18%
74,745
+2,518
+3% +$27.1K
PNNT
195
Pennant Park Investment Corp
PNNT
$228M
$750K 0.17%
216,246
+50,706
+31% +$210K
RWAY icon
196
Runway Growth Finance
RWAY
$277M
$679K 0.16%
121,023
+24,174
+25% +$153K
CION icon
197
CION Investment
CION
$349M
$673K 0.16%
108,061
+18,653
+21% +$130K
GSBD icon
198
Goldman Sachs BDC
GSBD
$1.09B
$642K 0.15%
67,747
-20,991
-24% -$195K
DFTX
199
Definium Therapeutics
DFTX
$4.95B
$622K 0.14%
13,220
-8,507
-39% -$210K
SLS icon
200
SELLAS Life Sciences
SLS
$2.28B
$617K 0.14%
+41,788
New +$288K
6 7
8
9 10

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.